Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways
Cardiovascular Diagnosis and Therapy · 2026-06 · 16 (3) · 50-50
DOI: 10.21037/cdt-2025-358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Diagnosis and Therapy, 2026-06. Verfasst von Li-Sha Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: The First Hospital of Shanxi Medical University, Taiyuan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Hospital of Shanxi Medical University, Taiyuan, China.
- Shanxi Medical University, Taiyuan, China.
- Department of Cardiology, The Affiliated Cardiovascular Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Geriatric Medicine, Shanxi Bethune Hospital. Taiyuan, China.
Zitieren
APA
Guo, L. S., Li, L., & Han, Q. H. (2026). Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways. Cardiovascular Diagnosis and Therapy, 16(3), 50-50. https://doi.org/10.21037/cdt-2025-358
Vancouver
Guo LS, Li L, Han QH. Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways. Cardiovascular Diagnosis and Therapy. 2026;16(3):50-50. doi:10.21037/cdt-2025-358
BibTeX
@article{Guo2026,
author = {Guo, Li-Sha and Li, Li and Han, Qing-Hua},
title = {Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways},
journal = {Cardiovascular Diagnosis and Therapy},
year = {2026},
volume = {16},
number = {3},
pages = {50--50},
doi = {10.21037/cdt-2025-358}
}
EUVIMED